Trials / Completed
CompletedNCT00403793
Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057)
A Phase II -b, Placebo-Controlled Trial Investigating the Efficacy, Safety and Pharmacokinetics of a Subcutaneous Etonogestrel Implant Combined With i.m. Testosterone Undecanoate for Male Contraception
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 350 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Male volunteers receive a new hormonal contraceptive consisting of an implant releasing a hormone and hormone injections in order to investigate the suppressive effect on sperm production and reversibility of sperm production after end of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | etonogestrel with testosterone undecanoate | 42 or 44 weeks with etonogestrel implant and testosterone undecanoate injections every 10 to 12 weeks |
| DRUG | Placebo | 42 or 44 weeks with placebo implant and placebo injections |
Timeline
- Start date
- 2003-10-01
- Primary completion
- 2006-12-01
- Completion
- 2006-12-01
- First posted
- 2006-11-27
- Last updated
- 2022-02-04
Source: ClinicalTrials.gov record NCT00403793. Inclusion in this directory is not an endorsement.